Pharmacists in Camden, AL Accepting Medicare
4 Pharmacists found. Showing 1 - 4
 Dr. John L Redwanski Jr., PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7 Camden Byp, Camden, AL 36726 Phone: 334-682-2900 |
 Mrs. Pamela Dunn Harper, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 212 Claiborne St, Camden, AL 36726 Phone: 334-682-9266 Fax: 334-682-4065 |
James Allen Stoudenmire, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 212 Claiborne St, Camden, AL 36726 Phone: 334-682-9266 Fax: 334-682-4065 |
Mike Burklow Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7 Camden Byp, Camden, AL 36726 Phone: 334-682-2900 |
News Archive
Researchers simplify and streamline guidelines for managing knee osteoarthritis
The burden of knee osteoarthritis is set to continue to increase around the world. Aging populations and rising levels of obesity, combined with an absence of a cure for the disease, will lead to an increased strain on health-care systems. Due to this, there is a focus on how to best manage the disease.
Loyola's new pediatric fast-track offers kid-friendly environment
Loyola University Health System's emergency room just got a little more kid-friendly with the opening a pediatric fast-track which will help provide better patient flow and satisfaction.
Blood test can predict recurrence of HPV-linked oral cancers
Research published yesterday indicates that recurrence of human papillomavirus (HPV)-induced cancers affecting the oropharynx (the area of the throat just behind the mouth) can be predicted by blood and saliva tests that screen for DNA fragments from HPV that have been shed by cancer cells.
Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review
Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.
› Verified 3 days ago